Cargando…
Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer
Autores principales: | Zhou, Xu, Hu, Kai, Bailey, Peter, Springfeld, Christoph, Roth, Susanne, Kurilov, Roma, Brors, Benedikt, Gress, Thomas, Buchholz, Malte, An, Jingyu, Wei, Kongyuan, Peccerella, Teresa, Büchler, Markus W., Hackert, Thilo, Neoptolemos, John P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061106/ https://www.ncbi.nlm.nih.gov/pubmed/37009482 http://dx.doi.org/10.3389/fcell.2023.1179559 |
Ejemplares similares
-
Clinical Impact of Molecular Subtyping of Pancreatic Cancer
por: Zhou, Xu, et al.
Publicado: (2021) -
Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival
por: Bailey, Peter, et al.
Publicado: (2023) -
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
por: Zhou, Xu, et al.
Publicado: (2023) -
Surgical Treatment of Pancreatic Ductal Adenocarcinoma
por: Wei, Kongyuan, et al.
Publicado: (2021) -
Deconstructing Pancreatic Cancer Using Next Generation-Omic Technologies–From Discovery to Knowledge-Guided Platforms for Better Patient Management
por: Schreyer, Daniel, et al.
Publicado: (2022)